Cyclic lipopeptides as antibacterial agents - Potent antibiotic activity mediated by intriguing mode of actions

International Journal of Medical Microbiology

Volumn 304, Issue 1, 2014, Pages 37-43

  Schneider, Tanja ^a,c   Müller, Anna ^a   Miess, Henrike ^b   Gross, Harald ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antibiotics; Cyclic lipopeptides; Daptomycin; Mode of action; Polymyxin

Indexed keywords

ACYLDEPSIPEPTIDE; AMFOMYCIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CYCLIC LIPOPEPTIDE; DAPTOMYCIN; EMPEDOPEPTINE; FATTY ACID; FRIULIMICIN; LIPOPEPTIDE; LOTILIBCIN; OLIGOPEPTIDE; PLUSBACIN; POLYMYXIN; RAMOPLANIN; TRIPROPEPTIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; LIPID COMPOSITION; NONHUMAN; SHORT SURVEY; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS; CYCLIC LIPOPEPTIDES; DAPTOMYCIN; MODE OF ACTION; POLYMYXIN;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HUMANS; LIPOPEPTIDES; PEPTIDES, CYCLIC;

EID: 84892511277     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2013.08.009     Document Type: Short Survey

References (85)

1. Ainsworth G.C., Brown A.M., Brownlee G. "Aerosporin". An antibiotic produced by Bacillus aerosporus Greer. Nature 1947, 160:263.
2. Allen N.E., Hobbs J.N., Alborn W.E. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob. Agents Chemother. 1987, 31:1093-1099.
3. Arnold T.M., Forrest G.N., Messmer K.J. Polymyxin antibiotics for gram-negative infections. Am. J. Health-Sys. Pharm. 2007, 64:819-826.
4. Ball L.-J., Goult C.M., Donarski J.A., Micklefield J., Ramesh V. NMR structure determination and calcium binding effects of lipopeptide antibiotic daptomycin. Org. Biomol. Chem. 2004, 2:1872-1878.
5. Baltz R.H., Miao V., Wrigley S.K. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat. Prod. Rep. 2005, 22:717-741.
6. Benedict R.G., Langlykke A.F. Antibiotic activity of Bacillus polymyxa. J. Bacteriol. 1947, 54:24-25.
7. Bergen P.J., Li J., Rayner C.R., Nation R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50:1953-1958.
8. Brötz H., Josten M., Wiedemann I., Schneider U., Götz F., Bierbaum G., Sahl H.G. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 1998, 30:317-327.
9. Brötz-Oesterhelt H., Beyer D., Kroll H.-P., Endermann R., Ladel C., Schroeder W., Hinzen B., Raddatz S., Paulsen H., Henninger K., Bandow J.E., Sahl H.-G., Labischinski H. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 2005, 111:1082-1087.
10. Bunkóczi G., Vértesy L., Sheldrick G.M. Structure of the lipopeptide antibiotic tsushimycin. Acta Cryst. Sect. D 2005, 61:1160-1164.
11. Canepari P., Boaretti M., Lleó M.M., Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob. Agents Chemother. 1990, 34:1220-1226.
12. Cavalleri B., Pagani H., Volpe G., Selva E., Parenti F. A-16686, a new antibiotic from Actinoplanes I. Fermentation, isolation and preliminary physico-chemical characteristics. J. Antibiot. 1984, 37:309-317.
13. Chen L., Yuan Y., Helm J.S., Hu Y., Rew Y., Shin D., Boger D.L., Walker S. Dissecting ramoplanin: mechanistic analysis of synthetic ramoplanin analogues as a guide to the design of improved antibiotics. J. Am. Chem. Soc. 2004, 126:7462-7463.
14. Ciabatti R., Kettenring J.K., Winters G., Tuan G., Zerilli L., Cavalleri B. Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic III. Structure elucidation. J. Antibiot. 1989, 42:254-267.
15. Cudic P., Kranz J.K., Behenna D.C., Kruger R.G., Tadesse H., Wand A.J., Veklich Y.I., Weisel J.W., McCafferty D.G. Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation. Proc. Natl. Acad. Sci. USA 2002, 99:7384-7389.
16. Debono M., Abbott B.J., Molloy R.M., Fukuda D.S., Hunt A.H., Daupert V.M., Counter F.T., Ott J.L., Carrell C.B., Howard L.C. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J. Antibiot. 1988, 41:1093-1105.
17. Debono M., Barnhart M., Carrell C.B., Hoffmann J.A., Occolowitz J.L., Abbott B.J., Fukuda D.S., Hamill R.L., Biemann K., Herlihy W.C. A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation. J. Antibiot. 1987, 40:761-777.
18. Dugourd D., Yang H., Elliott M., Siu R., Clement J.J., Straus S.K., Hancock R.E.W., Rubinchik E. Antimicrobial properties of MX-2401, an expanded-spectrum lipopeptide active in the presence of lung surfactant. Antimicrob. Agents Chemother. 2011, 55:3720-3728.
19. Dvorchik B., Arbeit R.D., Chung J., Liu S., Knebel W., Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob. Agents Chemother. 2004, 48:2799-2807.
20. Eliopoulos G.M., Willey S., Reiszner E., Spitzer P.G., Caputo G., Moellering R.C. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 1986, 30:532-535.
21. Evans M.E., Feola D.J., Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 1999, 33:960-967.
22. Fang X., Tiyanont K., Zhang Y., Wanner J., Boger D., Walker S. The mechanism of action of ramoplanin and enduracidin. Mol. Biosyst. 2006, 2:69-76.
23. Fujikawa K., Suketa Y., Hayashi K., Suzuki T. Chemical structure of circulin A. Experientia 1965, 21:307-308.
24. Hancock R.E.W. Peptide antibiotics. Lancet 1997, 349:418-422.
25. Harad K.I., Suzuki M., Kato A., Fujii K., Oka H., Ito Y. Separation of WAP-8294A components, a novel anti-methicillin-resistant Staphylococcus aureus antibiotic, using high-speed counter-current chromatography. J. Chromatogr. A 2001, 932:75-81.
26. Hashizume H., Hirosawa S., Sawa R., Muraoka Y., Ikeda D., Naganawa H., Igarashi M. Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. J. Antibiot. 2004, 57:52-58.
27. Hashizume H., Igarashi M., Hattori S., Hori M., Hamada M., Takeuchi T. Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. I. Taxonomy, isolation and biological activities. J. Antibiot. 2001, 54:1054-1059.
28. Hashizume H., Nishimura Y. Cyclic lipopeptide antibiotics. Studies in Natural Products Chemistry 2008, Vol. 35:693-751. Elsevier, Amsterdam.
29. Hashizume H., Sawa R., Harada S., Igarashi M., Adachi H., Nishimura Y., Nomoto A. Tripropeptin C blocks the lipid cycle of cell wall biosynthesis by complex formation with undecaprenyl pyrophosphate. Antimicrob. Agents Chemother. 2011, 55:3821-3828.
30. Heinemann B., Kaplan M., Muir R., Hooper I. Amphomycin, a new antibiotic. Antibiot. Chemother. 1953, 3:1239-1242.
31. Hermsen E.D., Sullivan C.J., Rotschafer J.C. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect. Dis. Clin. North Am. 2003, 17:545-562.
32. Ho S.W., Jung D., Calhoun J.R., Lear J.D., Okon M., Scott W.R.P., Hancock R.E.W., Straus S.K. Effect of divalent cations on the structure of the antibiotic daptomycin. Eur. Biophys. J. 2008, 37:421-433.
33. Hu Y., Helm J.S., Chen L., Ye X.-Y., Walker S. Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to lipid II. J. Am. Chem. Soc. 2003, 125:8736-8737.
34. Huber F., Pieper R., Tietz A. The formation of daptomycin by supplying decanoic acid to Streptomyces roseosporus cultures producing the antibiotic complex A21978C. J. Biotechnol. 1988, 7:283-292.
35. Jerala R. Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin. Investig. Drugs 2007, 16:1159-1169.
36. Johnson A. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Future Microbiol. 2006, 1:255-265.
37. Jung D., Powers J.P., Straus S.K., Hancock R.E.W. Lipid-specific binding of the calcium-dependent antibiotic daptomycin leads to changes in lipid polymorphism of model membranes. Chem. Phys. Lipids 2008, 154:120-128.
38. Jung D., Rozek A., Okon M., Hancock R.E.W. Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem. Biol. 2004, 11:949-957.
39. Kato A., Hirata H., Ohashi Y., Fujii K., Mori K., Harada K.-I. A new anti-MRSA antibiotic complex, WAP-8294A. II. Structure characterization of minor components by ESI LCMS and MS/MS. J. Antibiot. 2011, 64:373-379.
40. Kato A., Nakaya S., Ohashi Y., Hirata H., Fujii K., Harada K.-I. WAP-8294A 2, a novel Anti-MRSA antibiotic produced by Lysobacter sp. J. Am. Chem. Soc. 1997, 119:6680-6681.
41. Kato A., Nakaya S., Kokubo N., Aiba Y., Ohashi Y., Hirata H., Fujii K., Harada K. A new anti-MRSA antibiotic complex WAP-8294A. I. Taxonomy, isolation and biological activities. J. Antibiot. 1998, 51:929-935.
42. Kirstein J., Hoffmann A., Lilie H., Schmidt R., Rübsamen-Waigmann H., Brötz-Oesterhelt H., Mogk A., Turgay K. The antibiotic ADEP reprogrammes ClpP, switching it from a regulated to an uncontrolled protease. EMBO Mol. Med. 2009, 1:29-37.
43. Kleinkauf H., von Döhren H. Biosynthesis of peptide antibiotics. Ann. Rev. Microbiol. 1987, 41:259-289.
44. Konishi M., Sugawara K., Hanada M., Tomita K., Tomatsu K., Miyaki T., Kawaguchi H., Buck R.E., More C., Rossomano V.Z. Empedopeptin (BMY-28117), a new depsipeptide antibiotic. I. Production, isolation and properties. J. Antibiot. 1984, 37:949-957.
45. Koyama Y., Kurosasa A., Tsuchiya A., Takakuta K. A new antibiotic 'colistin' produced by spore-forming soil bacteria. J. Antibiot. 1950, 3:457-458.
46. Landman D., Georgescu C., Martin D.A., Quale J. Polymyxins revisited. Clin. Microbiol. Rev. 2008, 21:449-465.
47. Lee B.G., Park E.Y., Lee K.E., Jeon H., Sung K.H., Paulsen H., Rübsamen-Schaeff H., Brötz-Oesterhelt H., Song H.K. Structures of ClpP in complex with acyldepsipeptide antibiotics reveal its activation mechanism. Nat. Struct. Mol. Biol. 2010, 17:471-478.
48. Maki H., Miura K., Yamano Y. Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2001, 45:1823-1827.
49. Mascio C.T.M., Mortin L.I., Howland K.T., van Praagh A.D.G., Zhang S., Arya A., Chuong C.L., Kang C., Li T., Silverman J.A. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob. Agents Chemother. 2012, 56:5023-5030.
50. McCafferty D.G., Cudic P., Frankel B.A., Barkallah S., Kruger R.G., Li W. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 2002, 66:261-284.
51. Mengin-Lecreulx D., Allen N.E., Hobbs J.N., van Heijenoort J. Inhibition of peptidoglycan biosynthesis in Bacillus megaterium by daptomycin. FEMS Microbiol. Lett. 1990, 57:245-248.
52. Michel, K.H., Kastner, R.E., 1985. A54556 Antibiotics and process for production thereof. US Patent 4492650.
53. Mingeot-Leclercq M.-P., Tulkens P.M., Denamur S., Vaara T., Vaara M. Novel. polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 2012, 35:248-252.
54. 2+-dependent complex formation with peptidoglycan precursors. J. Biol. Chem. 2012, 287:20270-20280.
55. Nielsen T.H., Sørensen D., Tobiasen C., Andersen J.B., Christophersen C., Givskov M., Sørensen J. Antibiotic and biosurfactant properties of cyclic lipopeptides produced by fluorescent Pseudomonas spp. from the sugar beet rhizosphere. Appl. Environ. Microbiol. 2002, 68:3416-3423.
56. Pirri G., Giuliani A., Nicoletto S.F., Pizzuto L., Rinaldi A.C. Lipopeptides as anti-Infectives: a practical perspective. Cent. Eur. J. Biol. 2009, 4:258-273.
57. Pogliano J., Pogliano N., Silverman J.A. Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins. J. Bacteriol. 2012, 194:4494-4504.
58. Quale J., Shah N., Kelly P., Babu E., Backer M., Rosas-Garcia G., Salamera J., George A., Bratu S., Landman D. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporatory Gram-negative pathogens in New-York City. Microb. Drug Resist. 2012, 18:132-136.
59. Raaijmakers J.M., de Bruijn I., de Kock M.J.D. Cyclic lipopeptide production by plant-associated Pseudomonas spp.: Diversity, activity, biosynthesis, and regulation. MPMI 2006, 19:699-710.
60. Raaijmakers J.M., de Bruijn I., Nybroe O., Ongena M. Natural functions of lipopeptides from Bacillus and Pseudomonas: more than surfactants and antibiotics. FEMS Microbiol. Rev. 2010, 34:1037-1062.
61. Rew Y., Shin D., Hwang I., Boger D.L. Total synthesis and examination of three key analogues of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity. J. Am. Chem. Soc. 2004, 126:1041-1043.
62. Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J. Bacteriol. 1967, 93:1463-1464.
63. Roongsawang N., Washio K., Morikawa M. Diversity of nonribosomal peptide synthetases involved in the biosynthesis of lipopeptide biosurfactants. Int. J. Mol. Sci. 2011, 12:141-172.
64. Rotondi K.S., Gierasch L.M. A well-defined amphipathic conformation for the calcium-free cyclic lipopeptide antibiotic, daptomycin, in aqueous solution. Biopolymers 2005, 80:374-385.
65. Rubinchik E., Schneider T., Elliott M., Scott W.R.P., Pan J., Anklin C., Yang H., Dugourd D., Müller A., Gries K., Straus S.K., Sahl H.G., Hancock R.E.W. Mechanism of action and limited cross-resistance of new lipopeptide MX-2401. Antimicrob. Agents Chemother. 2011, 55:2743-2754.
66. Sader H.S., Rhomberg P.R., Jones R.N. Antimicrobial activity of a novel polymyxin analog (CB-182,804) tested against clinical strains of Gram-negative Bacilli, including colistin-resistant organisms. Poster #F1-1626 presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy 2010.
67. Sass P., Josten M., Famulla K., Schiffer G., Sahl H.-G., Hamoen L., Brötz-Oesterhelt H. Antibiotic acyldepsipeptides activate ClpP peptidase to degrade the cell division protein FtsZ. Proc. Natl. Acad. Sci. USA 2011, 108:17474-17479.
68. Sauermann R., Rothenburger M., Graninger W., Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology 2008, 81:79-91.
69. Schneider T., Gries K., Josten M., Wiedemann I., Pelzer S., Labischinski H., Sahl H.-G. The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob. Agents Chemother. 2009, 53:1610-1618.
70. Shaligram N.S., Singhal R.S. Surfactin - a review on biosynthesis, fermentation,.purification and applications. Food Technol. Biotechnol. 2010, 48:119-134.
71. Shoji J., Hinoo H., Katayama T., Matsumoto K., Tanimoto T., Hattori T., Higashiyama I., Miwa H., Motokawa K., Yoshida T. Isolation and characterization of new peptide antibiotics, plusbacins A1-A4 and B1-B4. J. Antibiot. 1992, 45:817-823.
72. Silverman J.A., Perlmutter N.G., Shapiro H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 2003, 47:2538-2544.
73. Singh P., Cameotra S.S. Potential applications of microbial surfactants in biomedical sciences. Trends Biotechnol. 2004, 22:142-146.
74. Somner E.A., Reynolds P.E. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother. 1990, 34:413-419.
75. Stansly P.G., Shepherd R.G., White H.J. Polymyxin: a new chemotherapeutic agent. Johns Hopk. Hosp. Bull. 1947, 81:43-54.
76. Storm D.R., Rosenthal K.S., Swanson P.E. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 1977, 46:723-763.
77. Straus S.K., Hancock R.E.W. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 2006, 1758:1215-1223.
78. Sugawara K., Numata K., Konishi M., Kawaguchi H. Empedopeptin (BMY-28117), a new depsipeptide antibiotic. II. Structure determination. J. Antibiot. 1984, 37:958-964.
79. Tam V.H., Schilling A.N., Vo G., Kabbara S., Kwa A.L., Wiederhold N.P., Lewis R.E. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa Antimicrob. Agents Chemother. 2005, 49:3624-3630.
80. Tanaka H., Oiwa R., Matsukura S., Omura S. Amphomycin inhibits phospho-N-acetylmuramyl-pentapeptide translocase in peptidoglycan synthesis of Bacillus. Biochem. Biophys. Res. Commun. 1979, 86:902-908.
81. Vaara M., Sader H.S., Rhomberg P.R., Jones R.N., Vaara T. Antimicrobial activity of the novel polymyxin derivative NAB739 tetsted against Gram-negative pathogens. J. Antimicrob. Chemother. 2012, 10.1093/jac/dks438.
82. Walker S., Chen L., Hu Y., Rew Y., Shin D., Boger D.L. Chemistry and biology of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity. Chem. Rev. 2005, 105:449-476.
83. Wilkinson S., Lowe L.A. Structures of the polymyxins A and the Question of Identity with the polymyxins M. Nature 1966, 212:311.
84. Williams D.H. The glycopeptide story - how to kill the deadly 'superbugs'. Nat. Prod. Rep. 1996, 13:469-477.
85. Zavascki A.P., Goldani L.Z., Li J., Nation R.L. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 2007, 60:1206-1215.